Bayer Aktiengesellschaft (SWX:BAYN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 34.00B +53.9% |
| Revenue (ttm) | 41.84B -2.9% |
| Net Income | -1.99B |
| EPS | -2.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.45 |
| Dividend | 0.10 (0.28%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 2 |
| Average Volume | 226 |
| Open | 33.89 |
| Previous Close | 35.84 |
| Day's Range | 33.89 - 33.89 |
| 52-Week Range | 32.75 - 41.28 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer granted priority review for asundexian by FDA
Bayer (BAYRY) announced that the FDA has accepted the company’s new drug application and granted priority review designation for its investigational oral Factor XIa inhibitor, asundexian, for the prev...
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT'S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priori...
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer's Monsanto unit on Monday said it would pay at least $133 million to settle Michigan and Rhode Island's claims that the company contaminated the states' natural resources with toxic chemicals ...
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has granted HYRNUO Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-smal...
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a camp...
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Aktiengesellschaft ETR: BAYN executives said the company's Crop Science division remains on track with a five-year plan centered on cost savings, margin expansion and a slate of product launches...
Bayer launches 2026 campaign to expand food access with Luke Bryan
Bayer (BAYRY) and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer…
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America...
Bayer Aktiengesellschaft Q1 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN reported first-quarter 2026 results that management said were in line with expectations, as growth in Crop Science and Consumer Health offset flat performance in Pha...
Bayer Net Profit Surges Driven by Growth in Agricultural Division
The group's net profit was aided by a gain from the sale of an antibiotics business and stronger underlying earnings at its agricultural division.
Bayer Q1 operating profit up 9% as crop protection unit gains
Bayer on Tuesday said first-quarter operating profit gained 9%, driven mainly by its agricultural business.
Bayer reports REVEAL study met primary endpoints
Bayer (BAYRY) announced topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evu...
Bayer to acquire Perfuse Therapeutics for $300M upfront
Bayer (BAYRY) and Perfuse Therapeutics announced an agreement under which Bayer will fully acquire Perfuse Therapeutics. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a...
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital that evaluated...
Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels
ST. LOUIS--(BUSINESS WIRE)--Bayer, a life science company, and bp, a global integrated energy company, today announced that they have entered into a long-term strategic alliance to jointly scale the c...
Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
Bayer said on Wednesday new analyses showed its experimental blood thinner asundexian reduced the incidence and severity of ischaemic strokes.
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneer...
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new la...
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
BERLIN--(BUSINESS WIRE)--A new study from Leaps by Bayer and BCG reveals varying trends in how the public views breakthrough science in China, Germany, and the United States.
Bayer upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Bayer (BAYRY) to Buy from Neutral with a EUR 56 price target
Bayer shares slide after U.S. Supreme Court split over Bayer's fight against Roundup lawsuits
Shares in chemicals giant Bayer fell as much as 6.5% on Tuesday after the U.S. Supreme Court appeared split over what view it will form in Bayer's fight against Roundup lawsuits.
With Bayer at US Supreme Court, MAHA rallies against pesticides
"Make America Healthy Again" activists rallied at the U.S. Supreme Court building on Monday against Bayer as the justices heard arguments in the German company's effort to end thousands of lawsuits t...
US Supreme Court hears Bayer's fight against Roundup lawsuits
The U.S. Supreme Court is set on Monday to consider Bayer AG's effort to shut down thousands of lawsuits accusing the company of failing to warn users that the active ingredient in its Roundup weedki...